Safety and efficacy of intratympanic ciprofloxacin otic suspension post-tubes in a real-world pediatric population

OTO-201 demonstrated otorrhea rates consistent with Phase 3 trials in a broader, real-world, ENT practice-based pediatric population. Outcomes were similar in Medicaid- and non-Medicaid insured patients. OTO-201 was well-tolerated.